New neoantigen approaches from Abogen and Odimma
ABO2109 and ODI-2001 are starting their first human studies.
Aktis takes a second asset into human trials
The recent Nasdaq entrant prepares to move AKY-2519 into the clinic.
EHA 2026 preview – Bristol’s celmod reveal
Golcadomide and iberdomide are set to feature at EHA.
Fianlimab flunks its big test
A Libtayo combo fails to beat Keytruda in first-line melanoma.
EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
EHA 2026 preview – BeOne versus Nurix in the front line
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
MacroGenics changes its tune on Linnet
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
Imfinzi squares up to Keytruda with a Padcev combo
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
